Skip to content
Research Article Open access CC BY 4.0

Comparison of the Immunogenicity and Pathogenicity of a Genetically Engineered Infectious Bursal Disease Virus Vaccine and Two Commercial Live Vaccines in Chickens with Maternal Antibodies

Erfan Ullah Chowdhury, Momota Rani Paul, Shukes Chandra Badhy, M. Rafiqul Islam

Asian Journal of Research in Animal and Veterinary Sciences · pp. 253–260 · Published 3 Dec 2018

10.9734/AJRAVS/2018/45190

Abstract

The objective of this study was to determine the immunogenicity and pathogenicity of an experimental infectious bursal disease virus (IBDV) live vaccine, BD3-tc, derived by genetic engineering from a Bangladeshi very virulent IBDV strain. Two commercial live IBDV vaccines, D-78 and 228E, were included for comparison. Two-hundred 1-day-old commercial layer chickens were raised in relative isolation and at 14 days of age the chickens were divided into 4 groups in 4 separate houses. Three groups were vaccinated intraocularly with the BD3-tc or D-78 or 228E at 14 and 21 days of age and the fourth group served as an unvaccinated control. At 21, 28, and 35 days of age, chickens were individually weighed, bled, and necropsied. The bursa of Fabricius (BF) from each chicken was collected, weighed, formalin fixed, and examined histologically. The immunogenicity was evaluated by serum antibody titer to IBDV as measured by an enzyme linked immunosorbent assay. The pathogenicity was analyzed by bursa/body-weight (B/Bw) ratio and gross and histopathological lesions in BF. The chickens were found to have high maternal antibody (mAb) titers (mean titer = 7324 on day 3). Following primary vaccination, no significant level of acquired antibody was observed in any of the vaccine groups. However, on day 35, two weeks after booster, the 228E group had nearly unchanged and the BD3-tc group had a slight increase of antibody titer. In contrast, antibody level in the D-78 group continued to decline. No significant changes in B/Bw ratios and bursal lesion scores were observed in any of the vaccine groups. Together, these findings show that high mAb titers in chicks can interfere with the take of IBDV vaccines, however, the 228E and BD3-tc vaccines are capable of breaking through the mAb at a relatively higher level as compared to the D-78.

Infectious bursal disease virus IBDV very virulent IBDV bursa of Fabricius IBDV vaccine maternal antibodies immunogenicity pathogenicity

References (10)

  1. 1 Biophysical and biochemical characterization of five animal viruses with bisegmented double-stranded RNA genomes [DOI]
  2. 2 Research on infectious bursal disease—the past, the present and the future [DOI]
  3. 3 Current status of vaccines against infectious bursal disease [DOI]
  4. 4 The genome of infectious bursal disease virus consists of two segments of double-stranded RNA [DOI]
  5. 5 Characteristics and Serologic Studies of Two Serotypes of Infectious Bursal Disease Virus in Turkeys [DOI]
  6. 6 Pathogenicity and Immunosuppressive Properties of Infectious Bursal Disease "Intermediate" Strains [DOI]
  7. 7 Molecular Characterization of Seven Chinese Isolates of Infectious Bursal Disease Virus: Classical, Very Virulent, and Variant Strains [DOI]
  8. 8 In vitro replication of infectious bursal disease virus in established lymphoid cell lines and chicken B lymphocytes [DOI]
  9. 9 Infectious bursal disease and hemorrhagic enteritis [DOI]
  10. 10 Infectious bursal disease virus type 1‐induced suppression of chicken lymphocyte response to mitogen [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

31

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.